Second, our finding of an association of RP-ILD with elevated serum imply BAFF-blocking therapy could be an attractive novel treatment for anti-MDA5+DM patients, especially patients with a tendency toward RP-ILD. The gene discussed is IFIH1; the disease is interstitial lung disease.